$2.2m sales rev for the Qtr $7m cash on hand $10.6m market cap @ 0.18 below ipo price @0.20 2 major distribution signed in 2 weeks flying under the radar IMO DYOR
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%